Prosecution Insights
Last updated: October 04, 2026
Application No. 18/210,416

GENETIC PLATFORM TO INVESTIGATE THE FUNCTIONS OF BACTERIAL DRUG EFFLUX PUMPS

Final Rejection §112
Filed
Jun 15, 2023
Priority
Jun 15, 2022 — provisional 63/352,569
Examiner
MORGAN, BAILEY MICHELLE
Art Unit
1645
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
UNIVERSITY OF GUELPH
OA Round
2 (Final)
56%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 56% of resolved cases
56%
Career Allowance Rate
18 granted / 32 resolved
-3.7% vs TC avg
Strong +58% interview lift
Without
With
+58.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
32 currently pending
Career history
64
Total Applications
across all art units

Statute-Specific Performance

§101
4.9%
-35.1% vs TC avg
§103
27.2%
-12.8% vs TC avg
§102
19.9%
-20.1% vs TC avg
§112
34.2%
-5.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 32 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Status The amended claim set filed on 7 April 2026 is acknowledged. Claims 1-20 are currently pending. Of those, claims 4-5 and 11 are amended. There are no new claims, and claims 11-20 are withdrawn. No claims are cancelled. Claims 1-10 will be examined on the merits herein. Response to Amendment Applicants’ arguments filed 7 April 2026 are acknowledged. For clarity, in this action, said arguments will be referred to as “Remarks” and the Non-Final Office Action mailed 9 January 2026 will be referred to as “NFOA”. Rejection(s) Withdrawn The rejection of claims 5 and 8-9 under 35 U.S.C. 112(b) is withdrawn in view of the claim amendments. The rejection of claim 4 under 35 U.S.C. 112(a) is withdrawn in view of the Applicants’ statement that the deposited strain will be publicly available upon issuance of a patent (Remarks, pg. 8). New Rejection(s) The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claim Rejections - 35 USC § 112(a) Claim 5 is newly rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection. Claim 5 has been amended to recite “an open variant of outer membrane ferric siderophore transporter FhuA, wherein the N-terminal plug domain of FhuA and four large external loops are removed,” but there does not appear to be a written description of the claim limitation “N-terminal plug domain” in the application as filed. Para. 192 of the instant specification describes an FhuA transporter which is rendered non-selective through “removal of a terminal plug domain and four large external loops,” but the specification does not teach which terminus to which the plug is attached. Applicant has pointed out para. 214 (Remarks pg. 6) as supporting this amendment. However, para. 214 does not describe the FhuA transporter or its open variant. Accordingly, the newly added limitation constitutes new matter. Allowable Subject Matter Claims 1-4 and 6-10 are allowed. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BAILEY M MORGAN whose telephone number is (703)756-5388. The examiner can normally be reached M-F 9-5 ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, SAMIRA JEAN-LOUIS can be reached at (571) 270-3503. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BAILEY M MORGAN/Examiner, Art Unit 1645 /SAMIRA J JEAN-LOUIS/Supervisory Patent Examiner, Art Unit 1642
Read full office action

Prosecution Timeline

Jun 15, 2023
Application Filed
Jan 09, 2026
Non-Final Rejection mailed — §112
Apr 07, 2026
Response Filed
Aug 11, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12729366
CULTURE BROTH FOR GRAM-POSITIVE BACTERIA
4y 6m to grant Granted Sep 08, 2026
Patent 12702685
ATTENUATED SALMONELLA GALLINARUM EXPRESSING FLIC OR FLIC-HIL2 AND USES THEREOF
2y 6m to grant Granted Aug 11, 2026
Patent 12667608
CONSTRUCTION METHOD OF RECOMBINANT DRUG-RESISTANT MYCOBACTERIUM BOVIS BACILLUS CALMETTE-GUERIN (BCG) STRAIN AND PHARMACEUTICAL COMPOSITION FOR TREATING TUBERCULOSIS (TB)
3y 10m to grant Granted Jun 30, 2026
Patent 12653845
METHOD FOR TREATING AND/OR PREVENTING A PARASITIC INFECTION IN A TELEOST
4y 2m to grant Granted Jun 16, 2026
Patent 12653875
LIVE ATTENUATED LEISHMANIA PARASITE VACCINES WITH ENHANCED SAFETY CHARACTERISTICS
4y 0m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
56%
Grant Probability
99%
With Interview (+58.3%)
3y 4m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 32 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month